Hixon Alison M, Micek Scott, Fraser Victoria J, Kollef Marin, Guillamet M Cristina Vazquez
Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.
Department of Pharmacy Practice, St Louis College of Pharmacy, St Louis, Missouri, USA.
Open Forum Infect Dis. 2024 Apr 26;11(5):ofae219. doi: 10.1093/ofid/ofae219. eCollection 2024 May.
Sepsis is a major cause of morbidity and mortality worldwide. When selecting empiric antibiotics for sepsis, clinicians are encouraged to use local resistance rates, but their impact on individual outcomes is unknown. Improved methods to predict outcomes are needed to optimize treatment selection and improve antibiotic stewardship.
We expanded on a previously developed theoretical model to estimate the excess risk of death in gram-negative bacilli (GNB) sepsis due to discordant antibiotics using 3 factors: the prevalence of GNB in sepsis, the rate of antibiotic resistance in GNB, and the mortality difference between discordant and concordant antibiotic treatments. We focused on ceftriaxone, cefepime, and meropenem as the anti-GNB treatment backbone in sepsis, pneumonia, and urinary tract infections. We analyzed both publicly available data and data from a large urban hospital.
Publicly available data were weighted toward culture-positive cases. Excess risk of death with discordant antibiotics was highest in septic shock and pneumonia. In septic shock, excess risk of death was 4.53% (95% confidence interval [CI], 4.04%-5.01%), 0.6% (95% CI, .55%-.66%), and 0.19% (95% CI, .16%-.21%) when considering resistance to ceftriaxone, cefepime, and meropenem, respectively. Results were similar in pneumonia. Local data, which included culture-negative cases, showed an excess risk of death in septic shock of 0.75% (95% CI, .57%-.93%) for treatment with discordant antibiotics in ceftriaxone-resistant infections and 0.18% (95% CI, .16%-.21%) for cefepime-resistant infections.
Estimating the excess risk of death for specific sepsis phenotypes in the context of local resistance rates, rather than relying on population resistance data, may be more informative in deciding empiric antibiotics in GNB infections.
脓毒症是全球发病和死亡的主要原因。在为脓毒症选择经验性抗生素时,鼓励临床医生使用当地的耐药率,但它们对个体预后的影响尚不清楚。需要改进预测预后的方法,以优化治疗选择并改善抗生素管理。
我们扩展了之前开发的理论模型,使用三个因素来估计革兰氏阴性杆菌(GNB)脓毒症中因抗生素不匹配导致的额外死亡风险:脓毒症中GNB的患病率、GNB中的抗生素耐药率,以及不匹配和匹配抗生素治疗之间的死亡率差异。我们将头孢曲松、头孢吡肟和美罗培南作为脓毒症、肺炎和尿路感染中抗GNB治疗的主要药物。我们分析了公开可用的数据以及一家大型城市医院的数据。
公开可用的数据偏向于培养阳性病例。在感染性休克和肺炎中,使用不匹配抗生素导致的额外死亡风险最高。在感染性休克中,考虑对头孢曲松、头孢吡肟和美罗培南的耐药性时,额外死亡风险分别为4.53%(95%置信区间[CI],4.04%-5.01%)、0.6%(95%CI,0.55%-0.66%)和0.19%(95%CI,0.16%-0.21%)。肺炎的结果相似。包括培养阴性病例的当地数据显示,在头孢曲松耐药感染中,使用不匹配抗生素治疗的感染性休克额外死亡风险为0.7�%(95%CI,0.57%-0.93%),在头孢吡肟耐药感染中为0.18%(95%CI,0.16%-0.21%)。
在当地耐药率的背景下估计特定脓毒症表型的额外死亡风险,而不是依赖总体耐药数据,可能在决定GNB感染的经验性抗生素时提供更多信息。